Projecten
NeuroCypres KU Leuven
Autonome creatie van analoge geïntegreerde schakelingen op basis van zelflerende ontwerpexpertise KU Leuven
Progress in semiconductor technology and in intelligent data processing are converging today, opening the door to countless smart ICT applications through the Cloud and Internet of Everything, to the people’s benefit in years to come. Applications that interact with the physical world (e.g. environmental sensing, healthcare, autonomous vehicles, etc.), also need analog integrated circuits in the cyber-physical or edge layer. But while digital ...
Identificatie van de moleculaire mechanismen van non-respons op behandelingen, terugvallen en remissie bij auto-immuunziekten, inflammatoire en allergische aandoeningen KU Leuven
3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The ...
Nieuw nanotechnologie-geschikt systeem voor endovasculaire in vivo nabij-infrarood fluorescentie moleculaire beeldvorming en endovasculaire nabij-infrarood gerichte fotodynamische therapie van atherosclerotische hartziekte. KU Leuven
CosmoPHOS-nano is a multidisciplinary, translational and business-oriented project, aiming to accomplish the following objectives:
- develop the CosmoPHOS system, which is a novel theranostic (diagnostic & therapeutic) nanotechnology-enabled portable combination system enabling endovascular in vivo near-infrared fluorescence molecular imaging, endovascular near-infrared targeted photodynamic therapy, real-time & follow-up ...
Gentherapie voor de behandeling van zeldzame erfelijke aritmogene cardiomyopathie KU Leuven
Development of a cure for rare cardiac diseases is a risky, costly and time-consuming process, which is hampered by insufficient insight into pathophysiological mechanisms of the diseases and lack of relevant disease models.
The GEREMY consortium proposes to overcome this challenge by developing a gene therapy (GT) for inherited arrhythmogenic cardiomyopathy (ACM), by targeting the disease-causing PLN (non-desmosomes) and PKP2 (cardiac ...
Gepersonaliseerde behandeling voor Cystic Fibrosis-patiënten met ultra-zeldzame CFTR-mutaties (en daarbuiten). KU Leuven
In our HIT-CF project, we aim to bring personalised disease modifying therapies to cystic fibrosis (CF) patients with ultra-rare CFTR mutations, who could otherwise never get access to such treatment. Once we have proven our unique concept, the CF community can easily extend our state-of-the-art methodology to all CF patients such that HIT-CF will impact the entire CF field.
We will achieve our goals by means of a randomised, ...
Europese activiteiten voor de ontwikkeling en implementatie van geneesmiddelen voor geavanceerde therapie in kaart brengen, meedoen en aansturen, ten behoeve van de patiënt en de samenleving KU Leuven
Advanced Therapy Medicinal Products (ATMPs) are medicines based on genes, cells and tissues for human use. They can provide patients novel treatment alternatives to significantly improve or even cure diseases that currently have no or inadequate standard-of-care options. However, significant challenges remain for the scientific, clinical and patient communities as well as commercial entities and regulatory, policy-making and ...
Microvasculaire verdunning bij vasculaire cognitieve stoornissen en hartfalen KU Leuven
Vascular dementia and heart failure represent major health burden to morbidity, mortality and quality of life. Comorbidities (hypertension, aging, diabetes, etc.) affect all organs, but the brain and heart are especially sensitive to these chronic stresses resulting in cognitive impairment (a mental disorder) and heart failure (a non-mental disorder). These comorbidities also induce a reduction in microvascular density, called microvascular ...
Europees gezamenlijk programma voor zeldzame ziekten KU Leuven
As recognized by the Council Recommendation 2009/C 151/02, rare diseases (RD) are a prime example of a research area that can strongly profit from coordination on a European and international scale. RD research should be improved to overcome fragmentation, leading to efficacious use of data and resources, faster scientific progress and competitiveness, and most importantly to decrease unnecessary hardship and prolonged suffering of RD ...